2017 American Transplant Congress
DC-SIGN Functionalized Porous Silicon Nanoparticles Targeting to Human and Non-Human Primate Dendritic Cells.
Porous silicon (pSi) nanoparticles, modified to specifically target DC, provide a novel platform to carry and deliver immunosuppressive drugs. The aim was to conjugate DC-SIGN…2017 American Transplant Congress
The Polymer Pro-Drug APP-103 Mitigates I/R Injury and Improves Graft Function in a Pre-Clinical Renal Transplant Model.
Purpose: Ischemia-reperfusion injury (IRI) is the strongest non-HLA factor that augments allogenicity of transplanted organs. Damage subsequent to IRI is critically linked to an abundance…2017 American Transplant Congress
The Associations Between Immunosuppression Use, Loss of Medicare and Kidney Allograft Outcomes.
Medicare coverage for kidney transplant recipients aged <65 years in the US ends 3 years posttransplant, but a significant proportion of recipients remain on Medicare…2017 American Transplant Congress
Is Once-Daily Extended-Release Tacrolimus Better Than Twice-Daily Standard-Release Tacrolimus? A Meta-Analysis of Randomized Controlled Trials.
Tacrolimus is one of the major immunosuppressants commonly used in transplant recipients. Extended-release tacrolimus is expected to have immunosuppressant effects equivalent to standard-release tacrolimus while…2017 American Transplant Congress
Impact of Donor Genotype on Recipient Tacrolimus Pharmacokinetics: The Liver Matters.
1U of Cinicnnati, Cincinnati; 2Cincinnati Children's, Cincinnati; 3iC42 Clinical Research, Colorado
Tacrolimus (Tac) is a cornerstone immunosuppressant metabolized in the gut and liver, resulting in high intra/inter patient pharmacokinetic (PK) variability. Recipient genotype (RG) impacts tac…2017 American Transplant Congress
Reduced Conversion from IgM Anti-HLA-DSA to IgG Anti-HLA-DSA in Belatacept-Treated vs. Cyclosporine-Treated Patients in BENEFIT and BENEFIT-EXT Trials.
Post-transplant, up to 50% of recipients develop IgM DSA. Half of these patients go on to develop IgG DSA. Importantly, patients that progress to IgG…2017 American Transplant Congress
Mesenchymal Stem Cells Suppress T Cell Proliferation and Improve Allograft Survival in a Nonhuman Primate Transplant Model.
Emory Transplant Center, Emory University, Atlanta, GA
Background: The clinical implementation of costimulation blockade (CoB) provides long-term benefit to transplant recipients, with the short-term drawback of increased acute rejection. Cellular therapies are…2017 American Transplant Congress
Emerging Safety and Tolerability of Obinutuzumab, a Type 2 Anti-CD20 Monoclonal Antibody for the Desensitization of Renal Transplant Candidates.
Background: Rituximab has limited efficacy for desensitizing allosensitized patients (pts) with end-stage renal disease (ESRD) and enabling kidney transplantation (KTx), however, tissue B-cell depletion is…2017 American Transplant Congress
Down but Not Out: Leucopenia Can Be Safely Treated with Reduction in Immunosuppression without Increasing Risk to the Kidney Allograft.
IntroductionLeucopenia is a growing problem with increasing immunosuppression (IS) in kidney transplantation. Reducing IS in the face of leucopenia is a concern due to the…2017 American Transplant Congress
Incidence of Donor-Specific Anti-HLA Antibodies in Non-HLA Sensitized Patients Given Tacrolimus Once or Twice Daily During the First Two Years Post-Transplantation.
Department of Nephrology and Organ Transplantation, Toulouse University Hospital, Toulouse, France
Donor-specific anti-HLA antibody (DSA)-mediated rejection (AMR) is a main cause of graft loss after kidney transplantation. Non-adherence is a risk factor for AMR and graft…
- « Previous Page
- 1
- …
- 88
- 89
- 90
- 91
- 92
- …
- 138
- Next Page »